CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions

Mark S Duxbury, Evan Matros, Thomas Clancy, Gerald Bailey, Michael Doff, Michael J Zinner, Stanley W Ashley, Anirban Maitra, Mark Redston, Edward E Whang

Research output: Contribution to journalArticlepeer-review

Abstract

The purpose of this study was to test the hypothesis that CEACAM6 expression is an indicator of adverse pathologic features and clinical outcome in pancreatic adenocarcinoma.
Original languageEnglish
Pages (from-to)491-6
Number of pages6
JournalAnnals of Surgery
Volume241
Issue number3
Publication statusPublished - 2005

Fingerprint Dive into the research topics of 'CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions'. Together they form a unique fingerprint.

Cite this